Andrea Sboner, PhD

Associate Professor

Pathology and Laboratory Medicine

Contact & profiles

ans2077@med.cornell.edu

Appointments

Associate Professor of Pathology and Laboratory MedicinePrimary
Pathology and Laboratory Medicine · 2022–
Associate Professor of Computational Genomics in Systems and Computational Biomedicine
Systems and Computational Biomedicine · 2025–
Associate Professor
Weill Cornell Graduate School — Computational Biology · 2019–

Past Appointments

Associate Professor of Computational Genomics in Computational Biomedicine
Systems and Computational Biomedicine · 2022–2025
Assistant Professor of Pathology and Laboratory Medicine
Pathology and Laboratory Medicine · 2013–2022
Assistant Professor of Computational Genomics in Computational Biomedicine
Systems and Computational Biomedicine · 2013–2022

Show all 5

Instructor in Pathology and Laboratory Medicine
Pathology and Laboratory Medicine · 2011–2013
Instructor of Computational Genomics in Computational Biomedicine
Systems and Computational Biomedicine · 2011–2013

Centers

Clinical & Translational Science Center
Englander Institute for Precision Medicine
Sandra and Edward Meyer Cancer Centerresearch
Cancer Genetics & Epigenetics

Education

Ph.D.
University of Trento (Italy), 2005
M.S.
University of Trento (Italy), 1998

Highlights

1
Thyroid : official journal of the American Thyroid Association · 2020
OEOlivier Elemento ASAndrea Sboner
PMID: 32948110PMCID: PMC8195874DOISenior author36 citations
2
NPJ precision oncology · 2026
BBBhavneet Bhinder MMMadhu M. Ouseph ASAlexandros Sigaras HBHimisha Beltran+7 more →ASAndrea Sboner
PMID: 42014463PMCID: PMC13287462DOI eCommonsSenior author2 citations

Publications

190

Funding

Active

8 grants

Co-I
The role of early oncogenic drivers in maintaining lineage fidelity in prostate cancer
National Cancer Institute · 2025–2030
R01CA301637-01
Co-I
Growth suppressive and oncogenic transcriptional programs controlled by the androgen receptor in prostate cancer
National Cancer Institute · 2025–2030
R01CA297829-01
Co-I
Upstream and downstream targeting of the SPOP ubiquitin signaling pathway in prostate cancer
National Cancer Institute · 2024–2029
R01CA287724-01A1
PI
Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population
Weill Cornell Medical College/Qatar · 2025–2027Contract
SA 252921-01
Co-I
Clonal Hematopoiesis as a determinant for bone marrow toxicities for targeted radiation therapies in prostate cancer.
U.S. Department of Defense · 2022–2027
W81XWH-22-1-0375
Co-I
Elucidating the Role of the Tumor Suppressor KEAP1 in Antitumor Immunity
National Cancer Institute · 2025–2027
R01CA296867-01A1
Co-I
Personalized in vitro models to advance precision health equity
National Cancer Institute · 2024–2027 · via Leidos Biomedical Research
HHSN261201500003I
Co-I
Pre-malignant mutation landscape and risk factors for progression to hematologic cancers
National Cancer Institute · 2021–2027
R01CA248747-01A1

Completed grants (14)

Co-I
Research collaboration agreement w/ Eli Lilly and Company
Eli Lilly and Company · 2019–2025BioPharma Alliance
ELC 202676-03
Co-I
Collaborative genomic alterations and transcriptional control in prostate cancer
National Cancer Institute · 2019–2025
R01CA233650-05
Co-I
Unraveling the landscape of homologous recombination deficiency in patients with breast and prostate cancer across the African diaspora in NYC
New York Genome Center Inc. · 2020–2024
NYG 204878-01
Co-I
G3BP1 Suppresses SPOP Ubiquitin Ligase to Promote Prostate Tumorigenesis
National Cancer Institute · 2018–2023
R01CA221152-01A1
Co-I
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
National Cancer Institute · 2017–2023
P50CA211024-05
KP
Improving the Diagnosis of Congenital Genitourinary Birth Defects
National Institute of Diabetes and Digestive and Kidney Diseases · 2018–2023
R01DK078121-11
KP
Personalized in vitro models to advance precision medicine
National Cancer Institute · 2019–2023 · via Leidos Biomedical Research
HHSN26100008
Co-I
The DARC side of Breast Cancer Disparities - African Ancestry and Cancer- Related Immune Response
National Cancer Institute · 2021–2023
R01CA259396-01
KP
The impacts of RNA-based classifiers on prostate cancer prognosis
Prostate Cancer Foundation · 2019–2021
PCF 19YOUN15
Co-I
Temporal Evolution of N-Myc Signaling and Early Targeting of the Neuroendocrine Phenotype in Prostate Cancer
U.S. Department of Defense · 2017–2020
W81XWH-17-1-0653
Co-I
Impact of Therapy on Modulation of Neuroendocrine-Associated Gene Expression in Patients With High Risk, Localized Prostate Cancer Treated With Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Alliance for Clinical Trials in Oncology · 2015–2018
ACT 15050798-02
Sub-PI
Large Oncosomes: A Novel Liquid Biopsy for Genetic Profiling in Patients with Castration Resistant Prostate Cancer
U.S. Department of Defense · 2016–2018 · via Cedars-Sinai Medical Center
W81XWH-16-1-0397
Co-I
Molecular Mechanics of Response to Combination Therapy in Early Lethal PCA
National Cancer Institute · 2016–2018 · via The Brigham & Women's Hospital INC
U10CA180821-04
KP
Comprehensive Prostate Cancer Characterization by Genomic and Transcriptomic Profiling
National Cancer Institute · 2011–2015
R01CA152057-03 EW

News mentions

6 View all WCM news ↗

Tumor Organoid Tech Advances Toward a Sci-Fi Future
July 20, 2026
Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators.
Prostate Cancer Foundation Awards Grants to Weill Cornell Medicine Investigators
March 26, 2026
Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation.
Students Design AI-Powered Health Solutions at Cornell Health Hackathon
March 19, 2026
More than 100 students from across Cornell campuses and 17 other universities gathered in New York City March 6–8 for the Cornell Health AI Hackathon.
Molecular Characterization Can Help Predict How Prostate Cancer Will Behave
May 17, 2021
Molecular characteristics detected in prostate cancers can provide clues that help predict how the disease will progress, according to new research from investigators at Weill Cornell Medicine and NewYork-Presbyterian.
Germline Whole-Exome Sequencing Reveals Potential New Treatment Opportunities in Bladder Cancers
December 8, 2020
A significant percentage of patients with urothelial cancers have inherited gene variants that drive the progression of these cancers, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

Show 1 more mention

Study Reveals Molecular Landscape of Enlarged Prostates, Suggests Treatment Strategy
April 24, 2020
Growth of the prostate is exceptionally common in aging men, leading to problems with urination. This overgrowth is not a tumor-like condition driven by gene mutations, and may be treatable in many cases with a class of drugs called mTOR inhibitors, according to a study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

External relationships

Other

Fondazione Heal Italia